EpiEndo is an Icelandic pharmaceutical and biotech startup company, primarily focused on solutions to chronic airway diseases. EpiEndo is the only company targeting Epithelial Barrier Failure (EBF) in respiratory diseases. Applying the paradigm of the “leaky epithelial barrier” both diagnostically and therapeutically makes EpiEndo a unique industry player and has enabled ways to disrupt the status-quo that has prevailed in the respiratory sector for decades.
Our company name stems from our view of the body’s Epithelial-Endothelial interfaces.
Our team includes Icelandic, Swedish and English medical biology and pharmaceutical experts and an experienced Scientific Advisory Board composed by important Key Opinion Leaders with a strong clinical and pharmacology background and extensive experience in managing international large projects.
The team members located at the Innovation House are EpiEndo’s COO Finnur Friðrik Einarsson and from time to time EpiEndo’s Founder and board member, Friðrik Rúnar Garðsson, MD.